Seth Karol

Has grant

Associate Member, Leukemia & Lymphoma Division

St. Jude Children's Research Hospital
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Recent Grants

Grant: Open

Sleep ALL Night: A Multicenter Trial to Prevent Sleep Disturbances in Pediatric Acute Lymphoblastic Leukemia

Open Date: 2027-05-01

Close Date: 2032-04-01

Grant: Open

A Phase 1 trial of menin-inhibitor ziftomenib in combination with chemotherapy for children with relapsed/refractory KMT2A-r/NUP98-r/NPM1-m acute leukemia (ITCC-101/APAL2020K, A subtrial of the PedAL/EuPAL relapsed acute leukemia master protocol)

Open Date: 2026-01-01

Close Date: 2027-01-01

Grant: Open

Precision Evolutionary Therapies for Relapsed pediatric Acute lymphoblastic Leukemia

Open Date: 2026-01-01

Close Date: 2031-12-01

Grant: Open

A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of (SC) Blinatumomab in Pediatric Participants with (R/R) and (MRD+) B-Cell Precursor Acute Lymphoblastic Leukemia (B-ALL) (AMG107)

Open Date: 2026-01-01

Close Date: 2027-01-01

Grant: Open

Risk stratified treatment for patients with newly diagnosed juvenile myelomonocytic leukemia (TRAZA) - T2020-004

Open Date: 2025-08-01

Close Date: 2035-08-01

Articles (23)

Year:

2025

Nudix hydrolase 15 (NUDT15) deficiency is strongly associated with thiopurine‐induced myelosuppression. Currently, testing for NUDT15 deficiency is based on the genotyping of the most frequent and clinically characterized no‐function variants, that is, * 2 , * 3 and * 9 . The Hispanic/Latino‐predominant variant NUDT15 * 4 (p.R139H) is classified as “uncertain function” by the Clinical Pharmacogenetics Implementation Consortium, because of insufficient data to ascertain its clinical actionability. In this study, we evaluated the association of NUDT15 * 4 with mercaptopurine (6‐MP) tolerance in a retrospective cohort of 1,399 patients with acute lymphoblastic leukemia (ALL) of diverse ancestries. All patients were wildtype for thiopurine methyltransferase gene. Patients were treated with 6‐MP in the context of ALL frontline clinical trials. The tolerated dose of 6‐MP was used to assess drug toxicity during the maintenance phase of ALL therapy. Patients with NUDT15 * 1 /* 4 ( n = 16, all of whom self‐identified as Hispanic/Latino) tolerated a significantly lower dose of 6‐MP than did those with NUDT15 * 1 /* 1 : median [interquartile range] of 39.0 [21.2–52.8] mg/m 2 , vs. 62.2 [47.9–71.6] mg/m 2 , P value < 0.001. No patient homozygous for * 4 was detected. In a separate retrospective validation study, six patients were identified as having NUDT15 * 1 /* 4 by routine clinical pharmacogenetics testing and tolerated a 6‐MP median dose of 38.7 mg/m 2 (IQR, 33.7–54.0), confirming the need for dose reduction attributed to the NUDT15 * 4 variant. These results point to the need to include NUDT15 * 4 in pharmacogenetics‐guided thiopurine dosing algorithms.

Year:

2025

Year:

2025

Children with ETV6::RUNX1 or high-hyperdiploid B-cell acute lymphoblastic leukemia (B-ALL) have favorable outcomes. The St. Jude (SJ) classification considers these patients low risk, regardless of their National Cancer Institute (NCI) risk classification, except when there is slow minimal residual disease (MRD) response or central nervous system/testicular involvement. We analyzed outcomes in children (aged 1-18.99 years) with these genotypes in the SJ Total XV/XVI studies (2000-2017). Patients with ETV6::RUNX1 (n = 222) or high-hyperdiploid (n = 296) B-ALL had 5-year event-free survival (EFS) of 97.7% ± 1.1% and 94.7% ± 1.4%, respectively. For ETV6::RUNX1, EFS was comparable between NCI standard-risk and high-risk patients and between SJ low-risk and standard-risk patients. Of the 40 NCI high-risk patients, 37 who received SJ low-risk therapy had excellent EFS (97.3% ± 2.8%). For high-hyperdiploid B-ALL, NCI high-risk patients had worse EFS than standard-risk patients (87.6% ± 4.5% vs 96.4% ± 1.3%; P = .016). EFS was similar for NCI standard-risk and high-risk patients classified as SJ low risk (96.0% ± 1.5% and 96.9% ± 3.2%; P = .719). However, EFS was worse for NCI high-risk patients than for NCI standard-risk patients receiving SJ standard/high-risk therapy (77.4% ± 8.2% vs 98.0% ± 2.2%; P = .004). NCI high-risk patients with ETV6::RUNX1 or high-hyperdiploid B-ALL who received SJ low-risk therapy had lower incidences of thrombosis (P = .013) and pancreatitis (P = .011) than those who received SJ standard/high-risk therapy. MRD-directed therapy yielded excellent outcomes, except for NCI high-risk high-hyperdiploid B-ALL patients with slow MRD response, who require new treatment approaches. Among NCI high-risk patients, 93% with ETV6::RUNX1 and 54% with high-hyperdiploid B-ALL experienced excellent outcomes with a low-intensity regimen. These trials were registered at www.clinicaltrials.gov as #NCT00137111 and #NCT00549848.

Year:

2025

Year:

2025

The prognosis of pediatric acute myeloid leukemia (AML) remains poor compared with pediatric acute lymphoblastic leukemia (ALL); accurate diagnosis and treatment strategies based on the genomic background are strongly needed. Recent advances in sequencing technologies have identified novel pediatric AML subtypes, including BCL11B structural variants and UBTF tandem duplications (UBTF-TD), associated with poor prognosis. In contrast, these novel subtypes do not fit into the diagnostic systems for AML of the 5th edition WHO classification or International Consensus Classifications (ICC) released in 2022. In this review, we describe the current state of pediatric AML classification in the context of a new classification framework based on the findings of updated genomic profiling. Molecular categories in the new classification system are associated with unique transcriptional, mutational, and clinical characteristics, which can be leveraged for predicting clinical outcomes and developing molecular-target therapies based on the initiating driver alterations. We also highlight four high-risk subtypes of pediatric AML, namely CBFA2T3::GLIS2, BCL11B, UBTF-TD, and ETS family fusions, focusing on their disease mechanisms, clinical associations, and possible therapeutic strategies to overcome the dismal clinical outcomes associated with these alterations.

Year:

2025

Background: Despite success in treating childhood acute lymphoblastic leukemia and lymphoma (ALL), modern multiagent chemotherapy regimens containing high-dose corticosteroids can result in osteonecrosis afflicting survivors, frequently involving the knee. Thus, we describe the usage of fresh osteoarticular allograft (FOAG) to treat steroid-induced osteonecrosis of the femoral condyle in pediatric cancer survivors. We assessed the efficacy of FOAGs to heal necrotic bone, provide long-term pain relief, while retrospectively reviewing quality of life and functional status. Methods: We recorded patient demographics, pain, and functional scores preoperatively, postoperatively, and at the most recent follow-up, additional surgical procedures, and radiographic outcomes at each timepoint. Anatomic locations and sizes of the grafts were noted using operative reports and intraoperative photographs. Function and pain scores were collected by direct patient communication or through survey, with data scored using the KOOS (Knee Injury and Osteoarthritis Outcome Score), PROMIS (Patient-Reported Outcomes Measurement Information System), and CTCAE (Common Terminology Criteria for Adverse Events) scoring tools. Results: Eighteen patients, (12 females) over a period of 8 years, underwent the procedure. One patient was excluded due to death before 12 months follow-up. The average age at diagnosis of femoral condyle osteonecrosis was 14.5 years. The average age at the time of surgery was 18.5 years (range, 13 to 25 y). All patients had at least 16 months follow-up (average 60 mo; range 16 to 99 mo). Grafts ranged in size from 18 to 27.5 mm. All patients reported a return to normal function of the knees with KOOS scores approaching normal, PROMIS scores averaging 46, and CTCAE outcomes improving at an average of 34 months post-surgery. Two patients experienced a partial graft failure, which was repaired with new allografts. Conclusions: Although historical reviews indicated unsatisfactory results, our experience highlights the successful usage of FOAG for the management of patients treated for childhood leukemia who develop steroid-induced osteonecrosis of the femoral condyle. This procedure proved effective in managing pain and improving function and quality of life, with good bone ingrowth despite large necrotic lesions. Levels of Evidence: Therapeutic Level IV.

Year:

2025

Relapse remains the leading cause of mortality in pediatric acute myeloid leukemia (AML), yet the genetic changes contributing to relapse remain incompletely defined. To address this gap, we performed whole-genome sequencing and targeted-capture sequencing on 39 diagnosis–relapse and 2 relapse–relapse pairs of pediatric AML. Mutational burden increased at relapse, largely reflecting spontaneous mutagenesis, whereas therapy-related signatures were rarely observed and only occasionally associated with pathogenic mutations. Although recurrently enriched mutations at relapse included those in FLT3 , WT1 , and TP53 , relapse-fated subclones were frequently marked only by non-pathogenic or non-coding variants. Longitudinal deep sequencing in eight patients showed rapid depletion of major clones after induction therapy, whereas subclones often displayed variable chemosensitivity. Relapse-specific mutations emerged only late or remained undetectable during remission, suggesting that clonal selection of pre-existing clones is the predominant mechanism of relapse. Transcriptome analysis of paired RNA sequencing data revealed no differentially expressed genes, but gene set enrichment analysis and CIBERSORT deconvolution in each pair uncovered heterogeneous trajectories to relapse. Although relapse is often attributed to the emergence of stem-like phenotypes, our data demonstrate that transcriptional evolution is more diverse: some cases acquired stem-like features, whereas others showed partial differentiation, which was confirmed by re-analysis of a public single cell RNA sequence dataset. These changes were largely constrained by baseline differentiation states at diagnosis. Together, our data indicate that pediatric AML relapse arises through selection of pre-existing clones with diverse trajectories, underscoring the need to target both stem-like and differentiated populations to achieve durable cures.

Year:

2025

Asparaginase is a critical component of modern therapy for acute lymphoblastic leukemia (ALL). Its use has improved cure rates for both children and adults with this disease. However, asparaginase therapy can be complicated by significant toxicities, including acute pancreatitis (AP). Such pancreatitis can be severe and result in life‐threatening or fatal complications. Here, we describe five cases of severe asparaginase‐induced pancreatitis in children receiving therapy for ALL. Despite maximal supportive care, these patients experienced severe symptoms and were unable to tolerate enteral nutrition (EN) initially after presentation. This case series highlights clinical features associated with intolerance to EN in this population. Providers should be mindful of these features when considering EN trials in patients with severe asparaginase‐associated AP. Some patients may require total parenteral nutrition to adequately support nutrition and recovery in severe asparaginase‐associated AP.

Year:

2025

Pediatric acute myeloid leukemia (AML) exhibits distinct genetic characteristics, including unique driver alterations and mutations with prognostic and therapeutic significance. Emerging rare, recurrent genetic abnormalities and their associations with outcomes emphasize the need for high-throughput molecular diagnostic tools. Whole genome sequencing (WGS) reliably detects key AML biomarkers such as structural variants, mutations, and copy number alterations. Whole transcriptome sequencing (WTS) complements WGS by uncovering oncogene expression patterns, allele-specific expression, and gene expression signatures. In this study, we describe an integrated WGS and WTS clinical workflow for routine pediatric AML diagnosis and present a systematic evaluation of its application compared to conventional cytogenetics and standard molecular diagnostic methods. Our findings demonstrate that the integrated WGS and WTS (iWGS-WTS) approach improves the identification of clinically relevant genetic alterations, enhancing precise disease classification and risk assessment. Moreover, with advancements in workflow and bioinformatics pipelines, the testing turnaround time can be optimized to meet the demands of clinical decision-making, positioning iWGS-WTS as a practical and superior alternative to traditional diagnostic methods in pediatric AML management.

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (19)

Rachael Stone

Assistant Professor

University of Virginia

UNITED STATES
View details

Yimei Li

Member

St. Jude Children's Research Hospital

UNITED STATES
View details

Mignon L. Loh

Professor

University of Washington

UNITED STATES
View details

Samuel Brady

Associate Professor, Clinical Medical Physicist

Cincinnati Children's Hospital Medical Center

UNITED STATES
View details

Keito Hoshitsuki

University of Pittsburgh

UNITED STATES
View details

Stephanie Dixon

Faculty

St. Jude Children's Research Hospital

UNITED STATES
View details

Kim Erika Nichols

Full Member

St. Jude Children's Research Hospital

UNITED STATES
View details

Kathryn Roberts

St. Jude Children's Research Hospital

UNITED STATES
View details

Daisuke Tomizawa

Head

National Center For Child Health and Development

JAPAN
View details

Tanja A. Gruber

Stanford University

UNITED STATES
View details

Arnaud Petit

MD, PhD, Prof

Sorbonne Université

FRANCE
View details

Ching-Hon Pui

Fahad Nasser Al-Rashid Chair of Leukemia Research

St. Jude Children's Research Hospital

UNITED STATES
View details

Jinghui Zhang

Professor

St. Jude Children's Research Hospital

UNITED STATES
View details

Joshua Wolf

St. Jude Children's Research Hospital

UNITED STATES
View details

Jiyang Yu

Interim Chair

St. Jude Children's Research Hospital

UNITED STATES
View details

SOM BISWAS

University of Tennessee Health Science Center

UNITED STATES
View details

Lu Wang

Medical Director, Molecular Pathology

St. Jude Children's Research Hospital

UNITED STATES
View details

Pandurang Kolekar

Sr. Computational Research Scientist

St. Jude Children's Research Hospital

UNITED STATES
View details

Charles Mullighan

Senior Deputy Director, St. Jude Children's Research Hospital Comprehensive Cancer Center

St. Jude Children's Research Hospital

UNITED STATES
View details